Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Novartis

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Novartis' 2013 sales performance.

Novartis

HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

J&J’s ponesimiod tops Aubagio in head-to-head MS trial J&J says it now intends to move ahead with marketing applications for ponesimod in the US and Europe and – if approved – it will be the first direct rival to Novartis’ ... So far Novartis and Biogen have been able to defend their patents on the

Gracell reports impressive data with one-day CAR-T for leukaemia

Gracell reports impressive data with one-day CAR-T for leukaemia Takes fight to Novartis and Gilead. Gracell Biotechnologies has thrown down a gauntlet to Novartis and Gilead Sciences with a CD19-targeting CAR-T for B-cell acute lymphoblastic leukaemia ... Those results suggest that FasT CAR19 – also known as GC007F)

Merck takes evobrutinib for MS into phase 3, on mixed data

Merck takes evobrutinib for MS into phase 3, on mixed data Novartis’ Gilenya (fingolimod) and Sanofi’s Aubagio (teriflunomide). ... It will also have to contend with newer drugs like Roche’s fast-growing injectable Ocrevus(ocrelizumab), Novartis’  Mayzent(siponimod) and potentially Biogen’s Tecfidera

Novartis’ CAR-T Kymriah scores SMC approval

Novartis’ CAR-T Kymriah scores SMC approval The drug picked up  EU approval for Kymriah last August, with Novartis quickly setting up a new manufacturing facility following production issues. ... Novartis’ CAR-T rival from Gilead, Yescarta, has a UK list price of nearly £300, 000 per patient.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics